Showing results (151-160 of 181) with videos related to
Sort By:
Pageof 19
Cancer|December 1, 1995
Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell supportH van der Lelie, J W Baars, S Rodenhuis, et al.Blood|June 1, 1995
Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantationM W Dercksen, W R Gerritsen, S Rodenhuis, et al.European Journal of Cancer (Oxford, England : 1990)|August 1, 1996
The toxicity of radiotherapy following high-dose chemotherapy with peripheral blood stem cell support in high-risk breast cancer: a preliminary analysisE van der Wall, C C Schaake-Koning, N van Zandwijk, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2000
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma GroupA Le Cesne, I Judson, D Crowther, et al.Annals of Surgical Oncology|April 8, 2010
The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapyM E Straver, E J Th Rutgers, S Rodenhuis, et al.Breast Cancer Research and Treatment|April 25, 2014
Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithmsC A Drukker, M V Nijenhuis, J M Bueno-de-Mesquita, et al.British Journal of Cancer|April 1, 1995
High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approachE van der Wall, W J Nooijen, J W Baars, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancerM T Huizing, L J van Warmerdam, H Rosing, et al.Lancet (London, England)|August 26, 1998
Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvementS Rodenhuis, D J Richel, E van der Wall, et al.European Journal of Cancer (Oxford, England : 1990)|September 6, 2003
Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II studyJ Verweij, A van Oosterom, J-Y Blay, et al.Pageof 19